{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-241942","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.337875+00:00","generated_at":"2026-06-10T08:32:35.717609+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaccinex presents pepinemab data at conferences; AD study completion expected Jun 2024, cancer ORR doubled","bullets":["Pepinemab presentations at Keystone Symposia (Oct 1-5) and CTAD (Oct 24-27) featuring AD and cancer data.","SIGNAL-AD phase 1/2a fully enrolled; last patient completes treatment by June 2024; key endpoints FDG-PET, CDR-SB, ADAS-Cog13.","KEYNOTE-B84: In PD-L1 low HNSCC (CPS<20), ORR 21.1% and median PFS 5.79 months, ~2x historical checkpoint monotherapy.","Combination with KEYTRUDA induces organized lymphoid structures correlated with disease control and PFS (p=0.0056).","Vaccinex and Merck in preliminary stages of potential extension study adding chemotherapy to pepinemab+KEYTRUDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-241942","json":"https://secwatch.observer/filing/0001193125-23-241942.json","markdown":"https://secwatch.observer/filing/0001193125-23-241942.md","text":"https://secwatch.observer/filing/0001193125-23-241942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523241942/0001193125-23-241942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523241942/d481466d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:32:35.717609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}